期刊文献+
共找到313篇文章
< 1 2 16 >
每页显示 20 50 100
Anti-proliferative effect of olmesartan on Tenon's capsule fibroblasts 被引量:4
1
作者 Xuan Wang Ya-Zhi Fan +1 位作者 Liang Yao Jian-Ming Wang 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2016年第5期669-676,共8页
AIM: To evaluate the inhibitive effect of olmesartan to fibroblast proliferation and the anti-scarring effect in Tenon's capsule, both in vitro and in vivo.· METHODS: Human primary Tenon's capsule fibroblasts... AIM: To evaluate the inhibitive effect of olmesartan to fibroblast proliferation and the anti-scarring effect in Tenon's capsule, both in vitro and in vivo.· METHODS: Human primary Tenon's capsule fibroblasts were cultured in vitro, treated with up titrating concentrations of olmesartan. The rate of inhibition was tested with methyl thiazol tetrazolium(MTT) method.Real-time PCR was performed to analyze changes in m RNA expressions of the fibrosis-related factors: matrix metalloproteinase-2(MMP-2), tissue inhibitor of metalloproteinase(TIMP-1,2) and proliferating cell nuclear antigen(PCNA). Thirty rabbits were divided into5 groups(3, 7, 14, 21, and 28d). A rabbit conjunctiva flap model was created in each eye. Olmesartan solution was injected subconjunctivally and then evaluated its anti-proliferation and anti-fibrosis effects through the histological morphology and immunohistochemistry of MMP-2 and PCNA in each group. Only the 7d group was treated with Masson's trichrome to compare the neovascularization in the subconjunctiva area.·RESULTS: In vitro, cultured Tenon's capsule human fibroblasts showed a dose dependent inhibition by olmesartan in MTT. Olmesartan reduced m RNA expressions of MMP-2 and PCNA but increased m RNA expressions of TIMP-1 and TIMP-2. In vivo, the rabbit eyes treated with olmesartan at 3rd, 7th, 14 thand 21stdays demonstrated a significant reduced expressions of MMP-2 and PCNA compared with control eye, no significant difference observed in 28 thday group. The cellular proliferation and neovascularization was suppressed by olmesartan in Masson's trichrome observation.·CONCLUSION: By inhibiting fibroblasts in vitro and in vivo, olmesartan prevents the proliferation and activity of fibroblasts in scar tissue formation, which might benefit glaucoma filtering surgery. 展开更多
关键词 olmesartan TRABECULECTOMY ANTI-PROLIFERATIVE matrix metalloproteinase-2 proliferating cell nuclear antigen
下载PDF
Angiotensin-Ⅱ inhibitor(olmesartan)-induced collagenous sprue with resolution following discontinuation of drug 被引量:1
2
作者 Jennifer A Nielsen Anita Steephen Matthew Lewin 《World Journal of Gastroenterology》 SCIE CAS 2013年第40期6928-6930,共3页
Collagenous sprue(CS) is a pattern of small-bowel injury characterized histologically by marked villous blunting,intraepithelial lymphocytes,and thickened sub-epithelial collagen table. Clinically,patients present wit... Collagenous sprue(CS) is a pattern of small-bowel injury characterized histologically by marked villous blunting,intraepithelial lymphocytes,and thickened sub-epithelial collagen table. Clinically,patients present with diarrhea,abdominal pain,malabsorption,and weight loss. Gluten intolerance is the most common cause of villous blunting in the duodenum; however,in a recent case series by the Mayo Clinic,it has been reported that olmesartan can have a similar effect. In this case report,a 62-year-old female with a history of hypothyroidism and hypertension managed for several years with olmesartan presented with abdominal pain,weight loss,and nausea. Despite compliance to a gluten-free diet,the patient's symptoms worsened,losing 20 pounds in 3 wk. Endoscopy showed thickening,scalloping,and mosaiform changes of the duodenal mucosa. The biopsy showed CS characterized by complete villous atrophy,lymphocytosis,and thickened sub-epithelial collagen table. After 2 mo cessation of olmesartan,the patient's symptoms improved,and follow-up endoscopy was normal with complete villous regeneration. These findings suggest that olmesartan was a contributing factor in the etiology of this patient's CS.Clinicians should be aware of the possibility of druginduced CS and potential reversibility after discontinuation of medication. 展开更多
关键词 COLLAGENOUS SPRUE CELIAC disease olmesartan Patient-drug interaction DUODENUM
下载PDF
抗高血压药Olmesartan 被引量:5
3
作者 范鸣 《药学进展》 CAS 2002年第2期120-121,共2页
关键词 降压药 药理作用 毒性 药动学 临床研究 抗高血压药 olmesartan
下载PDF
Rapid Simultaneous Determination of Olmesartan, —Amlodipine and Hydrochlorothiazide in Combined Pharmaceutical Dosage form by Stability-Indicating Ultra Performance Liquid Chromatography 被引量:1
4
作者 Kakumani Kishore Kumar Chimalakonda Kameswara Rao +1 位作者 G. Madhusudan Khagga Mukkanti 《American Journal of Analytical Chemistry》 2012年第1期50-58,共9页
A simple, precise and rapid stability-indicating ultra-performance liquid chromatography (UPLC) method was devel-oped for the simultaneous quantitative determination of Olmesartan, Amlodipine and Hydrochlorothiazide f... A simple, precise and rapid stability-indicating ultra-performance liquid chromatography (UPLC) method was devel-oped for the simultaneous quantitative determination of Olmesartan, Amlodipine and Hydrochlorothiazide from their innovative Pharmaceutical combination drug product, with the presence of degradation products. It involved a 50 mm × 2.1 mm, 1.8 μm Phenyl column. The separation was achieved on simple gradient method. The mobile phase A contains a mixture of sodium perchlorate buffer pH 3.2(0.053M): acetonitrile in the ratio 90:10, v/v, and mobile phase B con- tains a mixture of sodium perchlorate buffer pH 3.2(0.053M): acetonitrile in the ratio 10:90, v/v. The flow rate was 0.7 mL?min–1 and column temperature was maintained at 55?C.The gradient program (T/%B) was set as 0/10, 2/50, 4/80, and 6.0/10. The detector wavelength was 271 nm for Hydrochlorothiazide, 215 for Olmesartan and 237 nm for Amlodipine. The retention times of Olmesartan, Amlodipine, and Hydrochlorothiazide are 3.5, 3.3 and 0.9 minutes;respectively. The total runtime was 6.0 minutes within which three active compounds and their degradation products were separated. The described method was validated with respect to system suitability, specificity, linearity, precision and accuracy. The precision of the assay method was evaluated by carrying out six independent assays of Olmesartan, Amlodipine, and Hydrochlorothiazide (0.004 mg?mL–1, 0.001 mg?mL–1, 0.0025 mg?mL–1). The accuracy of the method was evaluated in triplicate at three concentration levels, i.e. 50%, 100%, and 150% of target test concentration. The described method was linear over the range, 2 to 6 μg?mL–1 for Olmesartan, 0.5 to 1.5 μg?mL–1 Amlodipine and 1.25 to 3.75 μg?mL–1 for Hydrochlorothiazide. The method is fast and is suitable for high-throughput analysis of the drug and one can analyze about 240 samples per working day, facilitating the processing of large-number batch samples. 展开更多
关键词 Validation olmesartan AMLODIPINE HYDROCHLOROTHIAZIDE and UPLC
下载PDF
Development and Validation of Stability Indicating LC Method for Olmesartan Medoxomil
5
作者 Chimalakonda Kameswara Rao Kakumani Kishore Kumar +4 位作者 Maddala VijayaLaxmi Polisetty Srinivasulu Gutta Madhusudhan Khagga Mukkanti Koduri Sai Venkata Srinivas 《American Journal of Analytical Chemistry》 2012年第2期153-160,共8页
The present method provides the detailed description of development and validation of a simple stability indicating re- verse phase column liquid chromatographic method for Olmesartan in the presence of its impurities... The present method provides the detailed description of development and validation of a simple stability indicating re- verse phase column liquid chromatographic method for Olmesartan in the presence of its impurities namely Imp-A, Imp-B, Imp-C, Imp-D, Imp-E, Imp-F and Imp-G and degradation products generated from forced degradation studies. The drug substance was subjected to stress conditions of aqueous hydrolysis, Oxidative, photolytic and thermal stress degradation. The degradation of Olmesartan was observed under acid hydrolysis, base hydrolysis and peroxide. The drug was found to be stable to other stress conditions attempted. Successful separation of the drug from synthetic impu- rities and degradation products formed under stress conditions was achieved on symmetry C18, 150 mm × 4.6 mm, 5μ column using a phosphate buffer, Acetonitrile and Milli Q water. The developed LC method was validated with respect to specificity, linearity, accuracy, precision, raggedness and robustness. The assay method was found to be linear in the range of 250 μg?mL–1 to with 1000 μg?mL–1 correlation coefficient of 0.9999 and the linearity of the impurities was es- tablished from LOQ to 0.4%. Recoveries of assay and impurities were found between 98.5% and 101.2%. The devel- oped LC method to determine the related substances and assay determinations of Olmesartan can be used to evaluate the quality of regular production samples and stability samples. To best of our knowledge, the validated stability indi- cating LC method which separates all the impurities disclosed in this investigation was not published elsewhere. 展开更多
关键词 olmesartan VALIDATION DEGRADATION PRODUCTS and RELATED Substances
下载PDF
Assessment of the Safety of Olmesartan in Combination with Sorafenib in Mice Bearing Ehrlich’s Ascites Carcinoma
6
作者 Mohammad M. Abd-Alhaseeb Sawsan A. Zaitone +1 位作者 Soad H. Abou-El-Ela Yasser M. Moustafa 《Journal of Cancer Therapy》 2013年第8期1355-1361,共7页
Sorafenib was the first multikinase inhibitor to be approved for use in metastatic renal cell carcinoma. Olmesartan medoxomil used in treatment of hypertension and was reported to inhibit angiogenesis in several model... Sorafenib was the first multikinase inhibitor to be approved for use in metastatic renal cell carcinoma. Olmesartan medoxomil used in treatment of hypertension and was reported to inhibit angiogenesis in several models. The present study was designed to assess the safety of a combination of sorafenib plus olmesartan compared to monotherapies in mice bearing Ehrlich’s ascites carcinoma cell line. Mice were divided to seven groups, 1) normal mice, 2) Ehrlich’s ascites carcinoma control, 3 - 5) olmesartan (3, 10, 30 mg/kg/day), respectively, 6) sorafenib (30 mg/kg/day) and 7) the combination group: mice received olmesartan (30 mg/kg/day) plus sorafenib. All drug treatments continued for 21 days. At the end of the experiment, a complete blood count was performed and kidney and liver functions were estimated. The combination therapy produced a non-significant change in most of the measurements of complete blood count and liver enzymes when compared to normal animals. On the other hand, the combined therapy significantly increased blood urea nitrogen when compared to normal group but did not change the serum creatinine level. Concomitant administration of olmesartan with sorafenib did not significantly augment the toxicity of the later. Therefore;olmesartan might be a safe candidate with sorafenib in treatment of cancer if clinical data proved the benefit of this combination. 展开更多
关键词 MICE Ehrlich’s ASCITES CARCINOMA olmesartan SORAFENIB
下载PDF
正常人血管紧张素Ⅱ受体拮抗剂(ARB)Olmesartan与血管反应的关系:与肾素—血管紧张素—醛固酮的关系
7
《高血压杂志》 CSCD 2004年第4期384-384,共1页
关键词 正常人 血管紧张素Ⅱ受体拮抗剂 ARB olmesartan 血管反应 肾素 血管紧张素 醛固酮
下载PDF
奥美沙坦酯olmesartan medoxmil
8
《中国医药技术与市场》 2007年第3期59-60,共2页
简介: 本品由(日)Sankyo Pharma和(美)Forest Laboratories共同开发,2002年6月首次在美国上市。
关键词 olmesartan 奥美沙坦酯 上市 美国
下载PDF
09017 Olmesartan的优点
9
作者 金伟秋 《国外药讯》 2001年第9期9-9,共1页
关键词 olmesartan 血管紧张素Ⅱ拮抗剂 药物申请 药物管理
下载PDF
日本推荐批准Olmesartan
10
作者 李燕燕 《国外药讯》 2004年第3期12-12,共1页
关键词 血管紧张素-2受体拮抗剂 olmesartan 日本 药品市场 抗高血压药物
下载PDF
抗高血压药 奥美沙坦酯olmesartan medoxmil
11
《中国医药技术与市场》 2007年第1期57-58,共2页
一、简介 本品由(日)Sankyo Pharma和(美)Forest Laboratories共同开发,2002年6月首次在美国上市。
关键词 olmesartan 抗高血压药 奥美沙坦酯
下载PDF
硝苯地平控释片联合奥美沙坦酯片治疗原发性高血压的临床效果分析
12
作者 赵贵生 吴国海 《系统医学》 2024年第19期99-102,共4页
目的 研究原发性高血压患者接受硝苯地平控释片以及奥美沙坦酯片联合干预的价值。方法 非随机选取2021年12月—2023年11月江苏省阜宁县人民医院进行治疗的68例原发性高血压患者作为研究对象,以治疗方法不同分为单一治疗组、结合治疗组,... 目的 研究原发性高血压患者接受硝苯地平控释片以及奥美沙坦酯片联合干预的价值。方法 非随机选取2021年12月—2023年11月江苏省阜宁县人民医院进行治疗的68例原发性高血压患者作为研究对象,以治疗方法不同分为单一治疗组、结合治疗组,单一治疗组采用奥美沙坦酯片治疗,结合治疗组采用硝苯地平控释片联合奥美沙坦酯片治疗。每组34例,记录两组患者血压、血脂指标变化情况。结果 干预后,结合治疗组患者的收缩压、舒张压均较单一治疗组优,差异有统计学意义(P均<0.05)。结合治疗组血压改善成功率较单一治疗组高,差异有统计学意义(P<0.05);结合治疗组血脂指标优于单一治疗组,差异有统计学意义(P均<0.05);结合治疗组不良反应发生率为14.71%(5/34),低于单一治疗组的29.41%(10/34),差异有统计学意义(χ^(2)=4.635,P<0.05)。结论 采用硝苯地平控释片与奥美沙坦酯片联合用药治疗原发性高血压,可有效调控血压及血脂,确保治疗安全有效。 展开更多
关键词 硝苯地平控释片 奥美沙坦酯片 原发性高血压 临床价值
下载PDF
Olmesartan Reduces New-onset Atrial Fibrillation and Atrial Fibrillation Burden after Dual-chamber Pacemaker Implantation in Atrioventricular Block Patients 被引量:3
13
作者 Hang Zhang Chang Pan Juan Zhang Lin-Lin Zhu Kai Huang Yun Zhong Zuo-Ying Hu 《Chinese Medical Journal》 SCIE CAS CSCD 2016年第18期2143-2148,共6页
Background: Atrial fibrillation (AF) is the rnost frequent tachyarrhythmia in patients with a permanent pacemaker. Angiotensin II receptor antagonists have a protective effect against the occurrence of AF in patien... Background: Atrial fibrillation (AF) is the rnost frequent tachyarrhythmia in patients with a permanent pacemaker. Angiotensin II receptor antagonists have a protective effect against the occurrence of AF in patients with heart diseases. This study aimed to assess the effectiveness of olmcsartan in the prevention of new-onset AF and AF burden in atrioventricular block (AVB) patients with dual-chamber (DDD) pacemaker implantation. Methods: This was a single-center, prospective, randomized, single-blind, controlled clinical study. A total of 116 AVB patients, who received DDD pacemakers implantation with the percentage of ventricular pacing (VP%) _〉40% from April 22, 2011 to December 24, 2012, were prospectively randomized to olrnesartan group (20 mg per day; n - 57) or control group (n = 59). Patients were lbllowed up using pacernaker prograrnming± 12-lead electrocardiography in the intrinsic sinus rhythm, laboratory examinations, and transthoracic echocardiography at 24 months. Atrial high rate events (AHREs) were defined as 180 beats/min over a minimum of 5 min. AF burden was calculated by the number of hours with AHREs divided by the number of measurement hours. Results: Ten (17.5%) patients in the olmesartan group and 24 patients (40.7%) in the control group occurred new-onset AF, and the difference between two groups was statistically significant (P = 0.04). AF burden was lower in olmesartan group than that in control group (8.02 ± 3.10% vs. 13.66 ± 6.14%, P = 0.04). There were no significant differences in mean days to the first occurrence of AHREs and mean cumulative numbers of AHREs between two groups (P = 0.89 and P = 0.42, respectively). Moreover, olmesartan group had smaller values of maximal P-wave durations and P-wave dispersion (PD) after 24 months follow-up compared with the control group ( 109.5 ± 7.4 ins vs. 113.4 ± 7.1 ms, P = 0.00; and 40.6 ± 4.5 ms vs. 43.3 ± 4.4 ins, P - 0.02, respectively). Left ventricular end-diastolic diameter and left ventricular qiection traction were not significantly diiTerent between two groups (both P 〉 0.05). Conclusion: This study suggested that 24-month ofolmesartan therapy could reduce new-onset AF and AF burden in patients with DDD pacemakers. 展开更多
关键词 Angiotensin II Receptor Antagonist Atrial Fibrillation olmesartan PACEMAKER Ventricular Pacing
原文传递
探讨奥美沙坦酯氢氯噻嗪片联合硝苯地平缓释片治疗高血压的临床效果
14
作者 乔金文 《中国实用医药》 2024年第17期10-13,共4页
目的分析奥美沙坦酯氢氯噻嗪片+硝苯地平缓释片治疗高血压的效果。方法88例高血压患者,随机分为对照组和观察组,每组44例。对照组给予常规对症治疗(硝苯地平缓释片),观察组在对照组的治疗基础上联合奥美沙坦酯氢氯噻嗪片治疗。比较两组... 目的分析奥美沙坦酯氢氯噻嗪片+硝苯地平缓释片治疗高血压的效果。方法88例高血压患者,随机分为对照组和观察组,每组44例。对照组给予常规对症治疗(硝苯地平缓释片),观察组在对照组的治疗基础上联合奥美沙坦酯氢氯噻嗪片治疗。比较两组患者治疗效果、血压、心功能指标、生活质量、不良反应发生情况。结果观察组患者治疗总有效率97.73%高于对照组的72.73%(P<0.05)。治疗后,观察组患者舒张压(82.15±2.12)mm Hg(1 mm Hg=0.133 kPa)、收缩压(125.27±3.09)mm Hg低于对照组的(87.32±7.15)、(141.29±8.47)mm Hg(P<0.05)。治疗后,观察组患者左心室壁厚度(9.26±0.56)mm、室间隔厚度(9.85±0.82)mm、左心室舒张末期内径(43.20±1.09)mm、左心室质量指数(117.28±12.09)g/m^(2)均低于对照组的(11.26±2.30)mm、(13.20±2.20)mm、(48.56±4.20)mm、(138.56±32.20)g/m^(2)(P<0.05)。治疗后,观察组患者活力状况评分(75.49±2.36)分、生理职能评分(75.93±2.08)分、情感职能评分(74.82±2.16)分、社会功能评分(74.82±2.09)分高于对照组的(62.59±8.15)、(62.39±8.26)、(62.39±8.26)、(62.39±8.22)分(P<0.05)。两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论在治疗高血压时,采取奥美沙坦酯氢氯噻嗪片+硝苯地平缓释片的方案,疗效显著,对患者血压与心功能指标的改善效果均较好,还可提升患者的生活质量,安全性较高。 展开更多
关键词 奥美沙坦酯氢氯噻嗪片 硝苯地平缓释片 高血压
下载PDF
补肾通络汤联合奥美沙坦酯治疗糖尿病肾病临床观察
15
作者 张帅 《实用中医药杂志》 2024年第3期447-449,共3页
目的:观察补肾通络汤联合奥美沙坦酯治疗糖尿病肾病(DN)的效果。方法:82例随机分为对照组和联合组各41例。两组均用奥美沙坦酯治疗,联合组加用补肾通络汤治疗。结果:总有效率联合组高于对照组(P<0.05)。治疗后联合组中医证候主症、... 目的:观察补肾通络汤联合奥美沙坦酯治疗糖尿病肾病(DN)的效果。方法:82例随机分为对照组和联合组各41例。两组均用奥美沙坦酯治疗,联合组加用补肾通络汤治疗。结果:总有效率联合组高于对照组(P<0.05)。治疗后联合组中医证候主症、次症、总积分低于对照组(P<0.05)。治疗后联合组FPG、Scr、mAlb、BUN低于治疗前(P<0.05)。治疗后两组MPO、CAT均降低而SOD升高,且联合组变化更为显著(P<0.05)。联合组治疗后Treg升高幅度大于对照组(P<0.05),而TH1、TH17/Treg值、TH1/TH2值降低幅度大于对照组(P<0.05)。结论:补肾通络汤联合奥美沙坦酯治疗DN疗效较好。 展开更多
关键词 糖尿病肾病 补肾通络汤 奥美沙坦酯
下载PDF
Olmesartan inhibits the expression of monocyte chemoattractant protein-1 and tumor necrosis factor-α and improves vascular remodeling after vascular injury in mouse
16
作者 李震 陈小东 +2 位作者 倪少凯 李建文 林木生 《Chinese Journal of Traumatology》 CAS 2004年第1期56-61,共6页
Objective: To investigate the neointima formation and the expression of monocyte chemoattractant protein 1 (MCP 1) and tumor necrosis factor α (TNF α) in cuff induced vascular injury in mouse model, and to examine t... Objective: To investigate the neointima formation and the expression of monocyte chemoattractant protein 1 (MCP 1) and tumor necrosis factor α (TNF α) in cuff induced vascular injury in mouse model, and to examine the effect of angiotensin II type 1 receptor (AT 1) blocker, olmesartan, on MCP 1 and TNF α expression and consequently vascular remodeling. Methods: Vascular injury was induced by polyethylene cuff placement around the mouse femoral artery. Some mice were treated with AT 1 receptor blocker, olmesartan, at the dose of 3 mg·kg -1 ·day -1 with an osmotic minipump. Neointima formation and the proliferation of vascular smooth muscle cells (VSMCs) were measured by morphometric analysis and bromodeoxyuridine (BrdU) incorporation. MCP 1 and TNF α expression was detected by Western blot and immunohistochemical staining. Results: We observed neointima formation 14 days after cuff placement as well as VSMCs proliferation in the media and neointima. Cuff placement also induced MCP 1 and TNF α expression in the media and neointima that the VSMCs specifically existed. Treatment of mice with olmesartan at a dose of 3 mg·kg -1 ·day -1 , which did not influence systolic blood pressure, significantly decreased neointima formation and the proliferation of VSMCs. Olmesartan also inhibited MCP 1 and TNF α expression in the injured arteries. Conclusions: Our results demonstrate that blockade of AT 1 receptor inhibits MCP 1 and TNF α expression and thereby improves vascular remodeling. 展开更多
关键词 Angiotensin II Monocyte chemoattractant protein 1 Tumor necrosis factor α INFLAMMATION
原文传递
AGTR1拮抗剂奥美沙坦对HTF凋亡的促进作用及其机制
17
作者 王丽君 李宏松 +3 位作者 张文怡 邵美琳 任梅梅 王建明 《中华实验眼科杂志》 CAS CSCD 北大核心 2023年第2期119-126,共8页
目的探讨血管紧张素1型受体(AGTR1)拮抗剂奥美沙坦(OMS)对人Tenon囊成纤维细胞(HTF)凋亡的作用及其机制。方法收集于西安交通大学第二附属医院行斜视手术的患者Tenon囊组织,采用组织块法培养原代HTF,vimentin免疫荧光染色及流式细胞术... 目的探讨血管紧张素1型受体(AGTR1)拮抗剂奥美沙坦(OMS)对人Tenon囊成纤维细胞(HTF)凋亡的作用及其机制。方法收集于西安交通大学第二附属医院行斜视手术的患者Tenon囊组织,采用组织块法培养原代HTF,vimentin免疫荧光染色及流式细胞术鉴定原代细胞。采用10 ng/ml转化生长因子β2(TGF-β2)诱导HTF建立细胞纤维化模型。将体外培养的细胞分为正常对照组、TGF-β2组、TGF-β2+OMS组和OMS组,各组细胞分别予以普通培养液、含TGF-β2的培养液、含TGF-β2和OMS的培养液、含OMS的培养液培养细胞48 h。Annexin V/PI染色流式细胞术检测细胞凋亡情况,分析细胞早期凋亡率、晚期凋亡率及总凋亡率。Western blot法检测线粒体凋亡途径中procaspase-9、cleaved caspase-9、bax和bcl-2蛋白表达水平。比色法检测细胞乳酸脱氢酶(LDH)、超氧化物歧化酶(SOD)活性。结果成功分离培养原代HTF,所培养细胞呈长梭形,vimentin免疫荧光染色呈阳性,流式细胞术检测所培养原代细胞中vimentin表达阳性率>99%。正常对照组、TGF-β2组、TGF-β2+OMS组和OMS组细胞早期凋亡率、晚期凋亡率、总凋亡率总体比较,差异均有统计学意义(F=24.92、3.96、41.82,均P<0.05),其中TGF-β2+OMS组早期凋亡率和总凋亡率较正常对照组和TGF-β2组明显升高,TGF-β2+OMS组晚期凋亡率较正常对照组明显升高,差异均有统计学意义(均P<0.05)。正常对照组、TGF-β2组、TGF-β2+OMS组和OMS组cleaved caspase-9/procaspase-9、bax、bax/bcl-2总体比较差异均有统计学意义(F=4.40、7.98、4.61,均P<0.05),其中TGF-β2+OMS组bax/bcl-2较正常对照组明显升高,TGF-β2+OMS组cleaved caspase-9/procaspase-9、bax、bax/bcl-2较TGF-β2组明显升高,差异均有统计学意义(均P<0.05)。正常对照组、TGF-β2组、TGF-β2+OMS组、OMS组细胞LDH活性值分别为(783.99±79.97)、(913.16±196.86)、(2529.06±240.21)、(2134.29±138.96)μmol/(min·L),总体比较差异有统计学意义(F=24.95,P<0.05),其中与正常对照组和TGF-β2组比较,TGF-β2+OMS组和OMS组LDH活性值明显升高,差异均有统计学意义(均P<0.05)。正常对照组、TGF-β2组、TGF-β2+OMS组、OMS组细胞SOD活性值分别为(50.35±0.97)、(41.61±4.56)、(28.88±3.26)、(37.61±4.83)μmol/(min·L),总体比较差异有统计学意义(F=5.71,P<0.05),其中TGF-β2+OMS组SOD活性值低于正常对照组和TGF-β2组,OMS组SOD活性值低于正常对照组,差异均有统计学意义(均P<0.05)。结论AGTR1拮抗剂OMS可以有效促进HTF凋亡,bax/bcl-2/caspase-9介导的线粒体凋亡途径及氧化应激途径可能是OMS调控HTF凋亡过程的潜在机制。 展开更多
关键词 青光眼 滤过手术 奥美沙坦 AGTR1拮抗剂 TENON囊成纤维细胞 凋亡
下载PDF
奥美沙坦酯联合骨化三醇治疗对早期2型糖尿病肾病患者炎症状态及肾间质纤维化的影响 被引量:6
18
作者 魏莉娟 郭姣姣 +1 位作者 何双红 王静 《临床和实验医学杂志》 2023年第4期364-367,共4页
目的研究奥美沙坦酯联合骨化三醇治疗对早期2型糖尿病肾病(T2DN)患者炎症状态及肾间质纤维化的影响。方法以回顾性分析为法,观察对象为2020年1月至2022年1月入四川大学华西医院的100例早期T2DN患者,根据不同治疗方法分为研究组(n=50)与... 目的研究奥美沙坦酯联合骨化三醇治疗对早期2型糖尿病肾病(T2DN)患者炎症状态及肾间质纤维化的影响。方法以回顾性分析为法,观察对象为2020年1月至2022年1月入四川大学华西医院的100例早期T2DN患者,根据不同治疗方法分为研究组(n=50)与对照组(n=50)。研究组联用奥美沙坦酯、骨化三醇治疗,对照组单用奥美沙坦酯治疗,持续用药8周。比较两组患者治疗前后炎症指标[C反应蛋白(CRP)、降钙素原(PCT)]、肾间质纤维化指标[血清同型半胱氨酸(Hcy)、血管内皮生长因子(VEGF)、转化生长因子β1(TGF-β1)]、血糖指标[糖化血红蛋白(HbA1c)、餐后2 h血糖(2 hPG)、空腹血糖]水平、肾功能指标[肾小球滤过率(GFR)、血尿素、血肌酐]水平与治疗后总有效率、不良反应(恶心呕吐、头晕头痛、发热、胃肠道反应)发生率。结果治疗8周后,两组患者的CRP、PCT、Hcy、VEGF、TGF-β1、HbA1c、2 hPG、空腹血糖、血尿素、血肌酐水平较治疗前明显下降,GFR较治疗前明显升高,差异均有统计学意义(P<0.05);研究组患者的CRP、PCT、Hcy、VEGF、TGF-β1、HbA1c、2 hPG、空腹血糖、血尿素、血肌酐水平为(14.36±2.04)mg/L、(1.21±0.08)μg/L、(13.79±1.72)μmol/L、(346.91±23.82)pg/mL、(152.97±18.92)pg/mL、(5.81±0.65)%、(8.36±1.24)mmol/L、(6.18±1.06)mmol/L、(4.27±1.08)mmol/L、(71.28±11.15)μmol/L,较对照组[(16.32±2.26)mg/L、(1.44±0.11)μg/L、(19.34±2.48)μmol/L、(394.36±25.11)pg/mL、(169.04±19.75)pg/mL、(6.42±0.76)%、(10.28±1.39)mmol/L、(7.81±1.12)mmol/L、(5.61±1.16)mmol/L、(78.41±12.37)μmol/L]更低,GFR为(93.85±8.62)mL·min^(-1)·1.73 m^(-2),较对照组[(86.29±8.93)mL·min^(-1)·1.73 m^(-2)]更高,差异均有统计学意义(P<0.05)。研究组患者的治疗总有效率为98.00%,明显高于对照组(84.00%),差异有统计学意义(P<0.05)。两组患者恶心呕吐、头晕头痛、发热、胃肠道反应发生率比较,差异无统计学意义(P>0.05)。结论奥美沙坦酯联合骨化三醇治疗早期T2DN患者的效果显著,可抑制患者炎症反应及肾脏纤维化,改善血糖及肾功能,且无明显副作用,安全性高。 展开更多
关键词 2型糖尿病肾病 奥美沙坦酯 骨化三醇 炎症状态 肾间质纤维化
下载PDF
骨化三醇治疗早期2型糖尿病肾病的临床效果 被引量:2
19
作者 黄程 邵云侠 +1 位作者 吴艳 邢昌赢 《中国医药导报》 CAS 2023年第33期92-95,共4页
目的观察骨化三醇治疗早期2型糖尿病肾病的临床效果。方法选取南京医科大学第一附属医院和安徽省芜湖市第二人民医院2019年8月至2022年5月收治的2型糖尿病肾病患者共90例为研究对象,采用随机数字表法将其分为两组,各45例。对照组在常规... 目的观察骨化三醇治疗早期2型糖尿病肾病的临床效果。方法选取南京医科大学第一附属医院和安徽省芜湖市第二人民医院2019年8月至2022年5月收治的2型糖尿病肾病患者共90例为研究对象,采用随机数字表法将其分为两组,各45例。对照组在常规治疗基础上给予奥美沙坦酯治疗,观察组在对照组基础上给予骨化三醇治疗,两组疗程均为8周。比较两组治疗前后肾功能[血肌酐(Scr)、尿白蛋白与肌酐比值(UACR)、微量蛋白尿(MA)、胱抑素C(CysC)],碱性磷酸酶(ALP),血压[舒张压(DBP)、收缩压(SBP)],血糖[空腹血糖(FBG)、糖化血红蛋白(Hb A1c)],NADPH氧化酶4(NOX4)及两组疗效,不良反应发生率。结果治疗后,两组Scr、UACR、MA、Cys C及对照组ALP较治疗前下降,且观察组Scr、UACR、MA、CysC低于对照组(P<0.05);观察组ALP较治疗前升高,且观察组高于对照组(P<0.05)。治疗后,两组SBP、DBP、FBG、Hb A1c均较治疗前降低(P<0.05),组间比较,差异无统计学意义(P>0.05)。治疗后,两组尿液NOX4较治疗前下降,且观察组低于对照组(P<0.05)。观察组疗效优于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论骨化三醇治疗早期2型糖尿病肾病患者能显著减轻肾功能损伤,提高疗效。 展开更多
关键词 骨化三醇 奥美沙坦酯 早期2型糖尿病肾病 疗效
下载PDF
益气固摄浓缩丸与奥美沙坦酯治疗慢性肾小球肾炎的效果评价
20
作者 傅奕 马伟 +6 位作者 李鑫 魏林 伍宏泽 吴兆东 陈帮明 付义 李金花 《中国医学创新》 CAS 2023年第24期54-59,共6页
目的:明确益气固摄浓缩丸治疗慢性肾小球肾炎(chronic glomerulonephritis,CGN)的效果与安全性。方法:筛选270例九江市中医医院2018年8月—2022年1月收治的CGN患者,根据随机数字表法分为对照组(n=135)及治疗组(n=135)。对照组采用基础治... 目的:明确益气固摄浓缩丸治疗慢性肾小球肾炎(chronic glomerulonephritis,CGN)的效果与安全性。方法:筛选270例九江市中医医院2018年8月—2022年1月收治的CGN患者,根据随机数字表法分为对照组(n=135)及治疗组(n=135)。对照组采用基础治疗,治疗组在对照组基础上施予益气固摄浓缩丸,两组治疗均持续3个月。检测并比较两组治疗前后尿红细胞计数、24 h尿蛋白定量、血清白蛋白(ALB)、尿素氮(BUN)、血肌酐(Scr)、甘油三酯(TG)、总胆固醇(TC)、α1微球蛋白(α1-MG)、视黄醇结合蛋白(RBP)、白介素-4(IL-4)、IL-10、γ干扰素(IFN-γ)、IFN-γ/IL-4、IFN-γ/IL-10,评估两组临床疗效、中医症候积分,详实记录不良反应发生情况。结果:治疗组总有效率(85.93%)高于对照组(71.85%)(P<0.05);治疗后,治疗组尿红细胞计数、24 h尿蛋白定量、BUN、Scr、ALB、TG、TC、α1-MG、RBP均优于对照组(P<0.05);与对照组比较,治疗后治疗组IL-4、IL-10水平均更高,IFN-γ、IFN-γ/IL-4及IFN-γ/IL-10水平均更低(P<0.05);治疗组治疗后中医症候积分、不良反应发生率均低于对照组(P<0.05)。结论:益气固摄浓缩丸通过调节免疫、抑制炎症、调脂、降尿蛋白等途径提高CGN临床疗效,改善疾病预后。 展开更多
关键词 慢性肾小球肾炎 益气固摄浓缩丸 奥美沙坦酯
下载PDF
上一页 1 2 16 下一页 到第
使用帮助 返回顶部